Skip to main content
. 2015 Aug 3;6(28):26090–26103. doi: 10.18632/oncotarget.4636

Figure 5. Effects of the combination dasatinib plus selumetinib on Ras-dependent human NSCLC models.

Figure 5

A. Percent of survival of H1299 and Calu3-ER cells treated for 72 hours with different concentrations of dasatinib, alone or in combination with selumetinib, as measured by MTT assay. **, 2-sided P < 0.01 versus selumetinib alone. B. Western blot analysis of H1299 and Calu3-ER cells treated for 3 hours with dasatinib, alone or in combination with selumetinib. The maximum doses used in MTT assays have been chosen for Western blot analysis.